FRONTEO Inc. (Headquarters: Minato-ku, Tokyo, President: Masahiro Morimoto, hereafter FRONTEO) is pleased to announce the new AI drug discovery system "liGALILEO (trademark pending, reading: Ligarileo) that will significantly change the conventional drug discovery process. ) ”, We will start the drug mining business *.

 

 

　The development of new drugs can be broadly divided into three categories: target search for new drug candidates, non-clinical studies that are verified using animals, and clinical trials that are actually administered to humans to finally verify efficacy and safety. There are two processes.However, among the candidate compounds that were seen as promising in the early stages of development, only 3 / 2 to 3 / 1 are actually commercialized as pharmaceuticals, and in addition to this, the development period is about 10 to 15 years. The development cost of 1000 billion yen has been a major issue in drug development for many years.

 

　Furthermore, in recent years, the number of published papers has dramatically increased due to the progress of medical and pharmaceutical research and computerization, and the cumulative total has reached more than 3000 million.The number has continued to increase, with more than one million new papers being added in the last year alone, and the current situation is that there is no limit to human decoding and analysis.

 

　liGALILEO uses the natural language analysis AI engine "Concept Encoder (trademark: conceptencoder, reading: concept encoder)" to comprehensively and efficiently analyze the potential of target molecules based on vast amounts of treatise information and medical and pharmaceutical data. To do.In addition, AI scores a wide variety of complex evaluation indicators such as scientific evaluation and marketability evaluation, which are indispensable when selecting targets.This is a system that can be called drug discovery process innovation.In addition to significantly improving the efficiency and speed of the drug discovery process, comprehensive and non-biased evaluation of information that is expected to increase further in the future, visualization of the evaluation process, construction of drug repositioning models, etc. This is expected to dramatically improve the success rate of conventional drug discovery processes.

 

　FRONTEO will further promote the drug mining business * that realizes the efficiency and speed of AI drug discovery with this system.

 

　The impact of this matter alone on the business results for the current fiscal year is minor, but we will promptly notify you if there are any matters to be disclosed.

 

* FRONTEO's business that supports the significant efficiency of new drug creation, drug reperpassing, and drug repositioning using proprietary AI.

 

■ About Concept Encoder　URL:https://lifescience.fronteo.com/technology/conceptencoder/
"Concept Encoder" is a natural language analysis AI (artificial intelligence) developed by FRONTEO specially in the life science field.It was developed in 2018 with the aim of effectively analyzing and utilizing medical data containing a large amount of free-form text data based on evidence. Concept Encoder can be co-analyzed with data other than text, and we are conducting research on co-analysis with numerical data such as gene expression information, vitals, and various test values ​​accumulated in the life science field.Patent registration number: Patent No. 6346367

■ About FRONTEO　URL:https://www.fronteo.com/
FRONTEO uses the in-house developed AI engines "KIBIT", "Concept Encoder", and "Looca Cross" that specialize in natural language processing to extract meaningful and important information from a huge amount of text data, and is a company. It is a data analysis company that supports the business of. Since its establishment in August 2003, it has been expanding globally to Japan, the United States, South Korea, and Taiwan, focusing on legal tech businesses such as "e-discovery (electronic discovery)" and "digital forensic investigation" that support corporate international litigation. Has been deployed.Based on the AI ​​technology cultivated in this business, we will expand the business field to the life science field, business intelligence field, and economic security from 8, and by using AI to "turn text data into knowledge", We contribute to solving various corporate issues such as drug discovery support, dementia diagnosis support, financial, personnel, and sales support. Listed on TSE Mothers on June 2014, 2007. Obtained a first-class medical device manufacturing and sales business license in January 6 (permit number: 26B2021X1), and notified the managed medical device sales business in September of the same year (notification number: 13 Minato Misei Equipment No. 1).The capital is 10350 thousand yen (as of March 9, 3).
* FRONTEO, KIBIT, and concept encoder are registered trademarks of FRONTEO in Japan.